title: Dietary conjugated linoleic acid decreases adipocyte size and favorably modifies adipokine status and insulin sensitivity in obese, insulin-resistant rats.
abstract: Conjugated linoleic acids (CLA) have been shown to alter adiposity in some species with varying effects on insulin resistance. The objective of this 8-week study was to investigate the effects of feeding a CLA mixture (1.5%, wt/wt) on adipocyte size, insulin sensitivity, adipokine status, and adipose lipid composition in fa/fa vs lean Zucker rats. The fa/fa CLA-fed rats had smaller adipocytes and improved insulin sensitivity compared with fa/fa rats fed the control diet. Conjugated linoleic acids did not affect select markers of adipose differentiation, lipid filling, lipid uptake, or oxidation. Dietary CLA, compared with the control diet, reduced circulating leptin and elevated fasting serum adiponectin concentrations in fa/fa rats. Adipose resistin messenger RNA levels were greater in fa/fa CLA-fed rats compared with fa/fa control rats. CLA did not markedly alter adipose phospholipid fatty acid composition, and the changes in the triacylglycerol fatty acid composition reflected a lower delta-9 desaturase index of CLA-fed vs control-fed rats. In conclusion, CLA reduced adipocyte size and favorably modified adipokine status and insulin sensitivity in fa/fa Zucker rats.
authors.affiliation: Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, Canada.
authors.forename: Amy
authors.initials: A
authors.lastname: Noto
authors.forename: Peter
authors.initials: P
authors.lastname: Zahradka
authors.forename: Natalia
authors.initials: N
authors.lastname: Yurkova
authors.forename: Xueping
authors.initials: X
authors.lastname: Xie
authors.forename: Han
authors.initials: H
authors.lastname: Truong
authors.forename: Evan
authors.initials: E
authors.lastname: Nitschmann
authors.forename: Malcolm R
authors.initials: MR
authors.lastname: Ogborn
authors.forename: Carla G
authors.initials: CG
authors.lastname: Taylor
mesh_terms: D017667:Adipocytes / Q000187:drug effects* / Q000378:metabolism*; D052242:Adiponectin / Q000378:metabolism*; D000273:Adipose Tissue / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D007333:Insulin Resistance / Q000502:physiology*; D007473:Ion Channels / Q000378:metabolism; D020738:Leptin / Q000235:genetics / Q000378:metabolism; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage*; D008071:Lipoprotein Lipase / Q000378:metabolism; D008297:Male; D024101:Mitochondrial Proteins / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D011924:Rats, Zucker; D052243:Resistin / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014280:Triglycerides / Q000378:metabolism; D000071246:Uncoupling Protein 2
chemical_list: D052242:Adiponectin; D007473:Ion Channels; D020738:Leptin; D044243:Linoleic Acids, Conjugated; D024101:Mitochondrial Proteins; D047495:PPAR gamma; D010743:Phospholipids; D052243:Resistin; D014280:Triglycerides; D000071246:Uncoupling Protein 2; D008071:Lipoprotein Lipase